Drug intelligence / Profile preview

USP506

Development stage: Preclinical
Lead developer: Uscare Pharm
Administration: Topical

Overview

USP506 is an early-stage research asset being developed by Uscare Pharm as a wound dressing. It is categorized under the company's 'Product Innovation' pipeline, which focuses on translating proprietary biomaterials into clinical applications. USP506 is designed to facilitate wound healing by providing a protective barrier and a scaffold that supports tissue regeneration. As of 2024, the product remains in the research phase, with its specific material composition likely leveraging Uscare Pharm's expertise in collagen-based biomaterials.

Beyond the preview

Go deeper on USP506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USP506.

Explore the full profile